All In Biotech

Drug Trial Radar · NCT06350825

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Evaluating the Efficacy and Safety of Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Apr 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 1, 2016

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Sponsor type
Academic, hospital or other
First posted
Apr 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)

Conditions

  • Metastatic Prostate Cancer
  • Therapy, Directly Observed

Interventions

  • Cytoreductive prostatectomy or brachytherapyProcedure

    local treatment+SOC for metastatic prostate cancer

  • ADT+second-generation antiandrogens ± chemotherapyDrug

    SOC(Triplet or doublet therapy) for mHSPC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. rPFSTime frame: 3 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.